Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Perez, Laurent"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-11 z 11
    Tytuł:
    High uptake of COVID-19 vaccines among healthcare workers in urban Uganda.
    Autorzy:
    Kyakuwa N; Uganda Virus Research Institute, Entebbe, Uganda.
    Kimbugwe G; MRC/UVRI & LSHTM Uganda Research Unit, Entebbe, Uganda.
    Nakanjako F; Uganda Virus Research Institute, Entebbe, Uganda.
    Kalute H; Uganda Virus Research Institute, Entebbe, Uganda.
    Mpooya S; Uganda Virus Research Institute, Entebbe, Uganda.
    Atuhairwe C; Uganda Martyrs University, Entebbe, Uganda.
    Perez L; University of Lausanne, Lausanne, Switzerland.
    Kikaire B; Makerere University College of Health Sciences, Kampala, Uganda.
    Pokaż więcej
    Źródło:
    PloS one [PLoS One] 2024 Apr 16; Vol. 19 (4), pp. e0277072. Date of Electronic Publication: 2024 Apr 16 (Print Publication: 2024).
    Typ publikacji:
    Journal Article
    MeSH Terms:
    COVID-19 Vaccines*
    COVID-19*/epidemiology
    COVID-19*/prevention & control
    Female ; Humans ; Adult ; Cross-Sectional Studies ; Uganda/epidemiology ; SARS-CoV-2 ; Health Personnel ; Vaccination
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Active PD-L1 incorporation within HIV virions functionally impairs T follicular helper cells.
    Autorzy:
    Munoz O; Services of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
    Banga R; Services of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
    Schelling R; Services of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
    Procopio FA; Services of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
    Mastrangelo A; Services of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
    Nortier P; Services of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
    Ohmiti K; Services of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
    Daraspe J; Electron Microscopy Facility, University of Lausanne, Lausanne, Switzerland.
    Cavassini M; Services of Infectious Diseases, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
    Fenwick C; Services of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
    Perez L; Services of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
    Perreau M; Services of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
    Pokaż więcej
    Źródło:
    PLoS pathogens [PLoS Pathog] 2022 Jul 05; Vol. 18 (7), pp. e1010673. Date of Electronic Publication: 2022 Jul 05 (Print Publication: 2022).
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    HIV Infections*
    T-Lymphocytes, Helper-Inducer*
    B-Lymphocytes ; Humans ; T Follicular Helper Cells ; Virion
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2.
    Autorzy:
    Low JS; Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.
    Vaqueirinho D; Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.
    Mele F; Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.
    Foglierini M; Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.
    Jerak J; Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.
    Perotti M; Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.
    Jarrossay D; Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.
    Jovic S; Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.
    Perez L; Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.
    Cacciatore R; Laboratory of Immunogenetics, Department of Transfusion Medicine and Immuno-Hematology, Fondazione I.R.C.C.S. Policlinico S. Matteo, 27100 Pavia, Italy.
    Terrot T; Clinical Trial Unit, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.
    Pellanda AF; Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, 6900 Lugano, Switzerland.
    Biggiogero M; Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, 6900 Lugano, Switzerland.
    Garzoni C; Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, 6900 Lugano, Switzerland.
    Ferrari P; Faculty of Biomedical Sciences, Università della Svizzera italiana, 6900 Lugano, Switzerland.; Department of Internal Medicine, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.; Prince of Wales Hospital Clinical School, University of New South Wales, Sydney, New South Wales 2052, Australia.
    Ceschi A; Clinical Trial Unit, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.; Faculty of Biomedical Sciences, Università della Svizzera italiana, 6900 Lugano, Switzerland.; Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland.; Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, 8091 Zurich, Switzerland.
    Lanzavecchia A; National Institute of Molecular Genetics, 20122 Milano, Italy.
    Sallusto F; Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland. .; Institute of Microbiology, ETH Zürich, 8093 Zurich, Switzerland.
    Cassotta A; Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland. .
    Pokaż więcej
    Źródło:
    Science (New York, N.Y.) [Science] 2021 Jun 18; Vol. 372 (6548), pp. 1336-1341. Date of Electronic Publication: 2021 May 18.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Immunodominant Epitopes*
    CD4-Positive T-Lymphocytes/*immunology
    COVID-19/*immunology
    SARS-CoV-2/*immunology
    Spike Glycoprotein, Coronavirus/*immunology
    Coronavirus/immunology ; Cross Reactions ; Epitopes, T-Lymphocyte/immunology ; Genes, T-Cell Receptor beta ; HLA-DP Antigens/immunology ; HLA-DR Antigens/immunology ; Humans ; Immunologic Memory ; Nucleocapsid Proteins/immunology ; Protein Domains ; Receptors, Antigen, T-Cell, alpha-beta/immunology ; Spike Glycoprotein, Coronavirus/chemistry ; T Follicular Helper Cells/immunology ; T-Lymphocyte Subsets/immunology
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Rationally designed Human Cytomegalovirus gB nanoparticle vaccine with improved immunogenicity.
    Autorzy:
    Perotti M; Institute for Research in Biomedicine, Università della Svizzera italiana, faculty of Biomedical Sciences, Bellinzona, Switzerland.; Institute of Microbiology, ETH Zürich, Zürich, Switzerland.
    Marcandalli J; Institute for Research in Biomedicine, Università della Svizzera italiana, faculty of Biomedical Sciences, Bellinzona, Switzerland.
    Demurtas D; BioEM Facility, School of Life Sciences, Swiss Federal Institute of Technology Lausanne (EPFL), Lausanne, Switzerland.
    Sallusto F; Institute for Research in Biomedicine, Università della Svizzera italiana, faculty of Biomedical Sciences, Bellinzona, Switzerland.; Institute of Microbiology, ETH Zürich, Zürich, Switzerland.
    Perez L; Institute for Research in Biomedicine, Università della Svizzera italiana, faculty of Biomedical Sciences, Bellinzona, Switzerland.; University of Lausanne (UNIL), Lausanne University Hospital (CHUV), Department of Medicine, Division of Immunology and Allergy, Center for Human Immunology (CHIL), Lausanne, Switzerland.
    Pokaż więcej
    Źródło:
    PLoS pathogens [PLoS Pathog] 2020 Dec 28; Vol. 16 (12), pp. e1009169. Date of Electronic Publication: 2020 Dec 28 (Print Publication: 2020).
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Nanoparticles*
    Antibodies, Viral/*immunology
    Cytomegalovirus Infections/*immunology
    Cytomegalovirus Vaccines/*immunology
    Viral Envelope Proteins/*immunology
    Animals ; Antibodies, Neutralizing/immunology ; Cytomegalovirus/immunology ; Cytomegalovirus Infections/prevention & control ; Female ; Humans ; Mice ; Mice, Inbred BALB C ; Vaccines, Subunit/immunology
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    AncesTree: An interactive immunoglobulin lineage tree visualizer.
    Autorzy:
    Foglierini M; Università della Svizzera italiana, Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Bellinzona, Switzerland.; Swiss Institute of Bioinformatics, Lausanne, Switzerland.
    Pappas L; Università della Svizzera italiana, Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Bellinzona, Switzerland.
    Lanzavecchia A; Università della Svizzera italiana, Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Bellinzona, Switzerland.
    Corti D; Humabs Biomed SA, Vir Biotechnology, Bellinzona, Switzerland.
    Perez L; Università della Svizzera italiana, Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Bellinzona, Switzerland.
    Pokaż więcej
    Źródło:
    PLoS computational biology [PLoS Comput Biol] 2020 Jul 10; Vol. 16 (7), pp. e1007731. Date of Electronic Publication: 2020 Jul 10 (Print Publication: 2020).
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Immunoglobulins*/chemistry
    Immunoglobulins*/classification
    Immunoglobulins*/genetics
    Software*
    Genes, Immunoglobulin/*genetics
    High-Throughput Nucleotide Sequencing/*methods
    Sequence Alignment/*methods
    Algorithms ; Cell Lineage/genetics ; Humans ; Phylogeny ; Sequence Analysis, DNA/methods
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Virus-Like Particles and Nanoparticles for Vaccine Development against HCMV.
    Autorzy:
    Perotti M; Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland.; Institute of Microbiology, ETH Zürich, 8093 Zürich, Switzerland.
    Perez L; Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland.; European Virus Bioinformatics Center, 07743 Jena, Germany.
    Pokaż więcej
    Źródło:
    Viruses [Viruses] 2019 Dec 28; Vol. 12 (1). Date of Electronic Publication: 2019 Dec 28.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't; Review
    MeSH Terms:
    Immunity, Humoral*
    Cytomegalovirus Infections/*prevention & control
    Nanoparticles/*administration & dosage
    Vaccines, Virus-Like Particle/*immunology
    Animals ; Antibodies, Neutralizing/immunology ; Antibodies, Viral/immunology ; Antigen Presentation ; Clinical Trials as Topic ; Cytomegalovirus ; Humans ; Immunocompromised Host ; Mice ; Nanoparticles/chemistry ; Viral Envelope Proteins/immunology
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    The C-terminal domain of TPX2 is made of alpha-helical tandem repeats.
    Autorzy:
    Sanchez-Pulido L; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, The University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.
    Perez L; Center for Genomic Regulation, C/ Dr Aiguader 88, 08003, Barcelona, Spain.; Institute for Research in Biomedicine, Università della Svizzera italiana, Via Vincenzo Vela 6, CH-6500, Bellinzona, Switzerland.
    Kuhn S; Faculty of Biology, Johannes-Gutenberg University, Gresemundweg 2, 55128, Mainz, Germany.
    Vernos I; Center for Genomic Regulation, C/ Dr Aiguader 88, 08003, Barcelona, Spain.
    Andrade-Navarro MA; Faculty of Biology, Johannes-Gutenberg University, Gresemundweg 2, 55128, Mainz, Germany. .; Institute of Molecular Biology, Ackermannweg 4, 55128, Mainz, Germany. .
    Pokaż więcej
    Źródło:
    BMC structural biology [BMC Struct Biol] 2016 Oct 26; Vol. 16 (1), pp. 17. Date of Electronic Publication: 2016 Oct 26.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Arabidopsis Proteins/*chemistry
    Cell Cycle Proteins/*chemistry
    Microtubule-Associated Proteins/*chemistry
    Nuclear Proteins/*chemistry
    Phosphoproteins/*chemistry
    Xenopus Proteins/*chemistry
    Amino Acid Sequence ; Animals ; Arabidopsis/metabolism ; Arabidopsis Proteins/genetics ; Arabidopsis Proteins/metabolism ; Cell Cycle Proteins/genetics ; Cell Cycle Proteins/metabolism ; Circular Dichroism ; Humans ; Microtubule-Associated Proteins/genetics ; Microtubule-Associated Proteins/metabolism ; Molecular Sequence Data ; Nuclear Proteins/genetics ; Nuclear Proteins/metabolism ; Phosphoproteins/genetics ; Phosphoproteins/metabolism ; Phylogeny ; Protein Structure, Secondary ; Protein Structure, Tertiary ; Recombinant Proteins/biosynthesis ; Recombinant Proteins/chemistry ; Recombinant Proteins/isolation & purification ; Sequence Alignment ; Xenopus/metabolism ; Xenopus Proteins/genetics ; Xenopus Proteins/metabolism
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody.
    Autorzy:
    Corti D; Institute for Research in Biomedicine, Università della Svizzera Italiana, CH-6500 Bellinzona, Switzerland. Humabs BioMed SA, 6500 Bellinzona, Switzerland.
    Misasi J; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
    Mulangu S; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
    Stanley DA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
    Kanekiyo M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
    Wollen S; U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA.
    Ploquin A; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
    Doria-Rose NA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
    Staupe RP; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
    Bailey M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
    Shi W; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
    Choe M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
    Marcus H; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
    Thompson EA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
    Cagigi A; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
    Silacci C; Institute for Research in Biomedicine, Università della Svizzera Italiana, CH-6500 Bellinzona, Switzerland.
    Fernandez-Rodriguez B; Institute for Research in Biomedicine, Università della Svizzera Italiana, CH-6500 Bellinzona, Switzerland.
    Perez L; Institute for Research in Biomedicine, Università della Svizzera Italiana, CH-6500 Bellinzona, Switzerland.
    Sallusto F; Institute for Research in Biomedicine, Università della Svizzera Italiana, CH-6500 Bellinzona, Switzerland.
    Vanzetta F; Humabs BioMed SA, 6500 Bellinzona, Switzerland.
    Agatic G; Humabs BioMed SA, 6500 Bellinzona, Switzerland.
    Cameroni E; Humabs BioMed SA, 6500 Bellinzona, Switzerland.
    Kisalu N; National Institute for Biomedical Research, National Laboratory of Public Health, Kinshasa B.P. 1197, Democratic Republic of the Congo.
    Gordon I; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
    Ledgerwood JE; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
    Mascola JR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
    Graham BS; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
    Muyembe-Tamfun JJ; National Institute for Biomedical Research, National Laboratory of Public Health, Kinshasa B.P. 1197, Democratic Republic of the Congo.
    Trefry JC; U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA.
    Lanzavecchia A; Institute for Research in Biomedicine, Università della Svizzera Italiana, CH-6500 Bellinzona, Switzerland. Institute of Microbiology, ETH Zürich, CH-8093 Zürich, Switzerland.
    Sullivan NJ; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA. .
    Pokaż więcej
    Źródło:
    Science (New York, N.Y.) [Science] 2016 Mar 18; Vol. 351 (6279), pp. 1339-42. Date of Electronic Publication: 2016 Feb 25.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Intramural
    MeSH Terms:
    Antibodies, Monoclonal/*administration & dosage
    Antibodies, Neutralizing/*administration & dosage
    Antibodies, Viral/*administration & dosage
    Ebolavirus/*immunology
    Hemorrhagic Fever, Ebola/*prevention & control
    Adult ; Animals ; Antibodies, Monoclonal/immunology ; Antibodies, Monoclonal/isolation & purification ; Antibodies, Neutralizing/immunology ; Antibodies, Neutralizing/isolation & purification ; Antibodies, Viral/immunology ; Antibodies, Viral/isolation & purification ; Clinical Trials as Topic ; Disease Outbreaks ; Female ; Hemorrhagic Fever, Ebola/epidemiology ; Humans ; Macaca ; Male ; Molecular Sequence Data ; Survivors
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Cross-neutralization of four paramyxoviruses by a human monoclonal antibody.
    Autorzy:
    Corti D; Humabs BioMed SA, Via Mirasole 1, 6500 Bellinzona, Switzerland. />Bianchi S
    Vanzetta F
    Minola A
    Perez L
    Agatic G
    Guarino B
    Silacci C
    Marcandalli J
    Marsland BJ
    Piralla A
    Percivalle E
    Sallusto F
    Baldanti F
    Lanzavecchia A
    Pokaż więcej
    Źródło:
    Nature [Nature] 2013 Sep 19; Vol. 501 (7467), pp. 439-43. Date of Electronic Publication: 2013 Aug 18.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Antibodies, Monoclonal/*immunology
    Antibodies, Neutralizing/*immunology
    Cross Reactions/*immunology
    Paramyxoviridae/*classification
    Paramyxoviridae/*immunology
    Paramyxoviridae Infections/*immunology
    Paramyxoviridae Infections/*virology
    Amino Acid Sequence ; Animals ; Antibodies, Monoclonal/chemistry ; Antibodies, Monoclonal/isolation & purification ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Neutralizing/chemistry ; Antibodies, Neutralizing/isolation & purification ; Antibodies, Neutralizing/therapeutic use ; Antibody Specificity/immunology ; Cattle ; Epitopes/immunology ; Humans ; Immunoglobulin Light Chains/chemistry ; Immunoglobulin Light Chains/immunology ; Immunoglobulin Variable Region/chemistry ; Immunoglobulin Variable Region/immunology ; Metapneumovirus/immunology ; Mice ; Models, Molecular ; Molecular Sequence Data ; Murine pneumonia virus/immunology ; Paramyxoviridae Infections/prevention & control ; Paramyxoviridae Infections/therapy ; Pneumovirus Infections/immunology ; Pneumovirus Infections/prevention & control ; Pneumovirus Infections/virology ; Respiratory Syncytial Virus Infections/immunology ; Respiratory Syncytial Virus Infections/prevention & control ; Respiratory Syncytial Virus Infections/therapy ; Respiratory Syncytial Virus Infections/virology ; Respiratory Syncytial Virus, Bovine/immunology ; Respiratory Syncytial Virus, Human/immunology ; Viral Fusion Proteins/chemistry ; Viral Fusion Proteins/immunology ; Viral Vaccines/chemistry ; Viral Vaccines/immunology
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Direct bacterial killing in vitro by recombinant Nod2 is compromised by Crohn's disease-associated mutations.
    Autorzy:
    Perez LH; Gastrointestinal Disease Area, Novartis Institutes for Biomedical Research, Horsham, United Kingdom.
    Butler M
    Creasey T
    Dzink-Fox J
    Gounarides J
    Petit S
    Ropenga A
    Ryder N
    Smith K
    Smith P
    Parkinson SJ
    Pokaż więcej
    Źródło:
    PloS one [PLoS One] 2010 Jun 01; Vol. 5 (6), pp. e10915. Date of Electronic Publication: 2010 Jun 01.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Mutation*
    Bacteria/*drug effects
    Crohn Disease/*genetics
    Nod2 Signaling Adaptor Protein/*pharmacology
    Crohn Disease/microbiology ; Humans ; Recombinant Proteins/pharmacology
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
      Wyświetlanie 1-11 z 11

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies